ASARFIHOSPITAL / Q4-FY26 / claim-ledger

Audit the questions that mattered.

Asarfi Hospital · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ4-FY26 · 2026-05-15Back to quarter ↗

Questions audited

11

Answered directly

68%

Numeric claims

3

Consistency

contradicted

Question ledger

What was answered, and how?

Nathan Gupta · investor

direct

Current situation of Aayushman scheme and its impact on hospitals.

Aishwand scheme is operational in our cancer hospital only. our focus primarily remains on on it scheme which has better package rates. our Aishman Bhar contribution to cancer hospital is around 15%.

Nathan Gupta · investor

direct

Capex required to increase bed capacity from 65 to 150.

Actually we don't require very high capex investment. It will be around 2 three cr rupes which will be met through internal approvals.

Nathan Gupta · investor

direct

Plans for mainboard migration.

Yes, we have decided that we will be migrating to mainboard. We are figuring out the eligibility criteria and process. We will be eligible after the month of July.

Kima C research · Research desk

partial

Reason for delay in bone marrow facility.

Basically in Jakartan organ transplant policy is very not in a good shape and we are trying to obtain approval for organ transplant facility. Delay is caused due to the procedural delay.

Kima C research · Research desk

partial

Status of proposed merger with another company.

There is delay because two three shareholders had died and the hairs have not inherited the shares. We are in continuous touch and hopefully it should be done this year.

Akarval · family office

partial

Reason for decrease in cancer patients and future expectations.

In the last quarter there was some scheme launched by government of Jarhand and there was some changes in the approval system. So there was administrative delay in the approval and that is why some few patients got decreased.

Akarval · family office

direct

Percentage of revenue from cancer segment and impact of delays.

they contribute to 10 10 12% of revenue and if in case of administrative delay there there will not be much impact to revenue.

Analyst · individual

direct

Forward guidance on EBITDA margins.

We are trying to bring case mix and margins in such a way that EBITDA remains at achieves 22 23 to 25%. This year we have achieved 20% EBITDA. We definitely would like to push it to at least 22% next year.

Analyst · individual

declined

Details of other income of 3.6 cr in March 2025.

I also understand details of order income will be mailed to you. I request you to kindly send this question on our email. We will send the breakups and details.

Analyst · car individual me

evasive

Confidence in achieving 260 cr top line by 2030.

Yes sir, we are working very hard and we should be able to achieve it.

Pashant Sharma · security

partial

Margins and utilization for cancer hospital facility.

To answer your question we require some number crunching and if you could write a mail to us we reply very specific. Just to give an overview that cancer hospital last year we had a revenue of 20 crores. This year we have achieved a revenue of 33 crores.

Pashant Sharma · security

partial

Key growth levers to reach 400 cr revenue with margin.

Major contribution will come from growth in the cancer hospital business because cancer hospital has not achieved its potential. We are at 42% of capacity utilization of 65 beds and we are going to increase the number of beds.